Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells.

Antibody 115

Antibody Immune Response Trials Clinical Trials 115

Medical Xpress

DECEMBER 6, 2022

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

Antibody 98

Antibody Vaccination Vaccine Immune Response 98

Bio Pharma Dive

OCTOBER 13, 2022

The findings, which were disclosed in a press release without specific data, are the first immune response results in humans for the reformulated shot targeting the BA.4 5 substrains.

Immune Response 169

Immune Response Antibody Trials 169

BioTech 365

FEBRUARY 10, 2021

Eurofins Launches Quantitative Antibody Test to Measure Immune Response to COVID-19 and Vaccines Eurofins Launches Quantitative Antibody Test to Measure Immune Response to COVID-19 and Vaccines LUXEMBOURG–(BUSINESS WIRE)–Eurofins launches a new CE marked serological assay for the identification and quantification … Continue reading (..)

Immune Response 52

Immune Response Antibody Vaccination Vaccine 52

Medical Xpress

JANUARY 17, 2023

Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.

Immune Response 107

Immune Response Vaccination Vaccine Antibody 107

Scienmag

JULY 8, 2022

Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The interdisciplinary study, published in Science Immunology, revealed how changing the flexibility of the antibody could stimulate a stronger immune response.

Antibody 86

Antibody Immune Response Scientist Research 86

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.

Immune Response 91

Immune Response Vaccination Vaccine Trials 91

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19.

Antibody 135

Antibody Immune Response Trials Protein 135

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

Immune Response 75

Immune Response Vaccination Vaccine Trials 75

Scienmag

DECEMBER 2, 2021

Peer-reviewed / Randomised Controlled Trial / People Randomised, phase 2 trial of COVID-19 booster vaccines finds seven increase immunity when given 10-12 weeks after two doses of Oxford-AstraZeneca, and six increase immunity following two doses of Pfizer-BioNTech. UK trial involving 2,878 adults […].

Immune Response 68

Immune Response Trials Antibody Vaccination 68

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma.

Antibody 92

Antibody Immune Response Vaccination Vaccine 92

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . Hugo Fry, CEO of RQ Bio, comments: “We’re delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.” .

Antibody 52

Antibody Development Immune Response Clinical Trials 52

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccination Vaccine Antibody 62

Medical Xpress

NOVEMBER 8, 2022

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Immune Response 67

Immune Response Vaccination Vaccine Antibody 67

Scienmag

SEPTEMBER 9, 2021

The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.

Immune Response 52

Immune Response Life Science Antibody Medicine 52

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy.

Protein 263

Protein Research Antibody Immune Response 263

Drug Discovery World

AUGUST 16, 2023

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Antibody 52

Antibody Immune Response Protein Research 52

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

Drug Discovery World

FEBRUARY 6, 2023

Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human immune system. MT: Can you provide me with an overview of what Infinimmune does currently and the potential it sees in the antibody-based therapeutics market?

Antibody 52

Antibody Immune Response Genome Genomics 52

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

Pharmaceutical Technology

MAY 22, 2023

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. .

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We

Immune Response 40

Immune Response Vaccination Vaccine Clinical Trials 40

Drug Discovery World

JANUARY 11, 2023

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . The post Collaboration to identify up to 10 novel target-antibody pairs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Engineer Immune Response Sales 52

Scienmag

OCTOBER 12, 2021

A quick stick in the arm with an approved COVID-19 vaccine elicits a flurry of activity in the body’s immune system. While much work has been done to study the antibodies produced in response to these vaccines, less is known about the response by the immune system’s T cells, which offer longer-term protection against the […].

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

BioSpace

SEPTEMBER 27, 2020

The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.

Immune Response 89

Immune Response Antibody Vaccination Vaccine 89

BioPharma Reporter

MARCH 30, 2021

COVID-19 mRNA vaccines are âhighly effectiveâ in producing antibodies against SARS-CoV-2 in pregnant and lactating women; and also confer protective immunity to newborns, according to a new study.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

BioSpace

SEPTEMBER 1, 2020

There is new research out of Iceland that suggests the body’s immune response to COVID-19 lasts longer than other research has suggested.

Immune Response 115

Immune Response Antibody Research 115

BioSpace

FEBRUARY 4, 2021

A new study report in Science suggests SARS-CoV-2 and its mutated new variants can evade immune responses via the selective deletion of small sections of the virus’s genetic sequence.

Immune Response 104

Immune Response Antibody Genetics 104

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 133

Immune Response Vaccination Vaccine Antibody 133

Drug Discovery World

AUGUST 25, 2023

For comparison, Schulz said, three new anti-amyloid antibodies used to treat AD have shown they slow disease progression by 25%, 27%, and 35%. Enhancing the efficiency of immune cells “We hypothesise that the reduced risk of AD associated with vaccines is likely due to a combination of mechanisms,” another researcher Avram Bukhbinder said.

Antibody 52

Antibody Vaccination Vaccine Protein 52

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Medical Xpress

MARCH 20, 2023

Although the population has developed specific immune responses due to previous infections and vaccinations, vaccinated and vulnerable individuals continue to contract COVID-19. Mutations of virus and illnesses caused by new variants are still to be expected even in a SARS-CoV-2 situation that has now become endemic.

Immune Response 75

Immune Response Antibody Vaccination Vaccine 75

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. It will then computationally re-assemble antigen-antibody pairs as potential starting points for the development of drugs.

Development 130

Development Bioinformatics Drugs Immune Response 130